Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.
It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.
With increased influenza activity anticipated this fall, U.S. public health officials and other leading medical experts today urged Americans to be vigilant and get immunized early for protection against seasonal influenza - a threat to Americans' health each and every year.
With the White House estimating that 30 to 50 percent of Americans will contract H1N1 flu this season, you’d think more people would be focused on prevention.
Pandemic swine flu can infect cells deeper in the lungs than seasonal flu can, according to a new study published today in Nature Biotechnology.
Pandemic swine flu can infect cells deeper in the lungs than seasonal flu can, according to a new study published today in Nature Biotechnology. The researchers, from Imperial College London, say this may explain why people infected with the pandemic strain of swine-origin H1N1 influenza are more likely to suffer more severe symptoms than those infected with the seasonal strain of H1N1.
In a national survey of businesses that looks at their preparations for a possible widespread H1N1 outbreak, Harvard School of Public Health (HSPH) researchers found that only one-third believe they could sustain their business without severe operational problems if half their workforce were absent for two weeks due to H1N1 (also known as "swine flu").
The National Autism Association (NAA) declared today as National "How Much Longer" Day for Autism, a day of letter-writing to the media, health agencies, Department of Education, lawmakers and the Obama Administration asking for such things as health insurance coverage, federal laws to protect special-ed students from dangerous restraint and seclusion practices in schools, safer vaccines, and for autism to be declared a nation health crisis.
Parents of school-aged children in every public and nonpublic school throughout Missouri will be able to receive instant updates about the H1N1 (Swine) flu as a result of a new, free service provided by the Missouri School Boards’ Association in collaboration with SchoolReach, a St. Louis-based school-to-parent notification and communications company. The service is available now to schools that do not already have an alert notification in place for parents.
Addressing a meeting of South East Asian health ministers Tuesday, WHO Director-General Margaret Chan said the H1N1 (swine) flu pandemic will "test the world on the issue of fairness" and "reveal in a measurable and tragic way the consequences of decades of failure to invest adequately in basic health systems and infrastructure,"
QIAGEN, today announced both the launch of a new Influenza A/H1N1 test and several updates to its activities in providing solutions for the global surveillance of the swine flu pandemic. QIAGEN’s new kit enables both the highly sensitive and specific detection of the novel Influenza A/H1N1, the virus that causes “swine flu”, as well as of all other known Influenza A and B virus strains.
General Data Company, Inc., which specializes in barcode-based error-proofing and tracking system solutions, is offering a new mobile application to help healthcare organizations administer employee vaccinations and track the immunization status of their personnel for H1N1, influenza, and other vaccinations.
The first trial testing a candidate 2009 H1N1 influenza vaccine in pregnant women is launching this week, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, announced today.
Scientists in China have discovered that roots of a plant used a century ago during the great Spanish influenza pandemic contains substances with powerful effects in laboratory experiments in killing the H1N1 swine flu virus that now threatens the world.
Promega announces the release of the Maxwell 16 Viral Total Nucleic Acid Purification Kit which, among other labs, currently serves the OCA Hospital in Mexico for H1N1 clinical research.
Blue Shield of California announced today that it will cover the administrative costs of the H1N1 virus (swine flu) vaccine for all its members, regardless of which plan they have. Blue Shield will be waiving prior authorizations, copays and deductibles for office visits when members go to an in-network doctor to get H1N1 vaccinations.
Cepheid (Nasdaq: CPHD) today announced the accelerated development of a Flu A (Influenza Virus) Panel test for use on the GeneXpert((R)) System. The test will be designed to provide 45-minute identification of Flu A infection, with specific presumptive identification of seasonal H1, seasonal H3, and H1N1 novel strain types.
The Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota is convening an international summit on the H1N1 influenza pandemic and critical business preparedness.
It is the start of the flu season and with seasonal influenza responsible for more than 36,000 deaths per year, getting a flu vaccine is critical. Today, Maxim Health Systems announced on October 1 it will launch its annual influenza vaccination program and will provide flu shots nationwide through more than 44,000 clinics.
Vangent, Inc., a leading global provider of information management and strategic business process outsourcing solutions, announced it has partnered with the Morehouse School of Medicine (MSM) in Atlanta, GA to provide job opportunities for some of Morehouse's second year graduate students pursuing a Master of Public Health (MPH) degree.
Amarillo Biosciences, Inc. (OTCBB: AMAR) today announced that a Phase 2 study of orally administered interferon-alpha for the prevention of influenza and winter colds has reached the midway point. The study in Perth, Australia achieved full target enrollment of 200 subjects and 98% of the subjects remain on study drug. Subjects in the study are receiving a lozenge containing interferon-alpha or a matching placebo once a day for 16 weeks.
Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading provider of vaccines in China, today announced that the first lot of PANFLU.1, its H1N1 vaccine, has passed the lot release process of China's National Institute for the Control of Pharmaceutical and Biological Products and obtained the Certificate for the Release of Biological Products, which means the released vaccines are ready for delivery.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.